A late-year growth upgrade sent shares higher to close out 2019.
News & Analysis: Bausch Health Companies
Despite a new name and a new management team, Bausch Health's controversial past still lingers in its heavily discounted stock price.
FDA announcements can make or break a stock. These four events are the most important ones this month.
Bausch's better-than-expected third-quarter numbers delighted investors last month.
BHC earnings call for the period ending September 30, 2019.
A big industry announcement took one of these stocks lower.
A lawsuit over the company's top-selling drug caused investors to worry.
BHC earnings call for the period ending August 6, 2019.
The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.
It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.